Read by QxMD icon Read


Bin Liu, Fusheng Gan, Yu Ge, Haiyang Yu
OBJECTIVE: The aim of this study is to investigate the clinical efficacy of percutaneous kyphoplasty (PKP) combined with zoledronic acid (aclasta) in the treatment and prevention of osteoporotic vertebral compression fractures (OVCF). METHOD: A total of 104 patients with OVCF were treated with PKP from February 15, 2014 to January 17, 2016. All patients were randomly assigned to control and experimental groups, each group having 52 patients. All patients in the control group were treated with PKP...
August 22, 2017: Journal of Investigative Surgery: the Official Journal of the Academy of Surgical Research
A Bergua, B Hohberger
Zoledronate-induced (Aclasta®) uveitis is a rare iatrogen-induced inflammation of ocular structures, which can result in substantial morphological and functional limitations. This case report describes the clinical course of a female patient with zoledronate-induced panuveitis. Additionally, the diagnostic procedure, therapy and follow-up are presented.
July 26, 2017: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
Sohita Dhillon
Zoledronic acid (Reclast® , Aclasta® ) is an intravenous, highly potent aminobisphosphonate approved worldwide, including in the USA, EU and Japan for use in patients with primary or secondary osteoporosis or low bone mass (approved indications vary between countries). Its high affinity to and long half-life in bone, and long duration of action, allow for once-yearly administration, which has the potential to improve adherence to therapy. Zoledronic acid once yearly for up to 3 years improved bone mineral density (BMD) at several skeletal sites, reduced fracture risk and bone turnover, and/or preserved bone structure and mass relative to placebo in clinical studies in patients with primary or secondary osteoporosis...
November 2016: Drugs
Sarah Davis, Marrissa Martyn-St James, Jean Sanderson, John Stevens, Edward Goka, Andrew Rawdin, Susi Sadler, Ruth Wong, Fiona Campbell, Matt Stevenson, Mark Strong, Peter Selby, Neil Gittoes
BACKGROUND: Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in fracture. OBJECTIVES: To evaluate the clinical effectiveness and safety of bisphosphonates [alendronic acid (Fosamax® and Fosamax® Once Weekly, Merck Sharp & Dohme Ltd), risedronic acid (Actonel® and Actonel Once a Week® , Warner Chilcott UK Ltd), ibandronic acid (Bonviva® , Roche Products Ltd) and zoledronic acid (Aclasta® , Novartis Pharmaceuticals UK Ltd)] for the prevention of fragility fracture and to assess their cost-effectiveness at varying levels of fracture risk...
October 2016: Health Technology Assessment: HTA
Lulu L C D Bursztyn, Moness Masri, Thomas G Sheidow
PURPOSE: To describe a case of retinal toxicity after intravenous administration of the bisphosphonate medication zoledronic acid. METHODS: A 61-year-old woman with known bull's eye chloroquine maculopathy presented with sudden decrease in vision within 1 week of receiving intravenous zoledronic acid (Aclasta). Complete ophthalmic examination including fundus photography, autofluorescence, optical coherence tomography, and visual field testing were performed over 1½ years of follow-up...
2014: Retinal Cases & Brief Reports
Amy Grenon
No abstract text is available yet for this article.
May 2013: Health Law in Canada
Agnès Räkel, Andrée Boucher, Louis-Georges Ste-Marie
Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between Zol and risedronate for new fractures. Improvements in bone mineral density and early reduction of bone remodeling markers are observed in postmenopausal osteoporosis, recent low-trauma hip fracture, and glucocorticoid-induced osteoporosis...
2011: Clinical Interventions in Aging
N F Izmerov, L A Shpagina, L A Panacheva, S A Karmanovskaia, G V Kuznetsova, A G Karpenko
Recommendations for patients with occupational locomotory disorders include ultrasonography, diagnostic and therapeutic arthroscopy, target therapy of systemic osteoporosis with monohydrate zoledronic acid (aclasta)--that enables prolong remission (up to 46.2 months).
2011: Meditsina Truda i Promyshlennaia Ekologiia
F Procianoy, E Procianoy
A 60-year-old woman received a single 5-mg dose of zoledronic acid (Aclasta) for treatment of postmenopausal osteoporosis. One day after receiving the drug, she acutely developed a painful periorbital swelling, chemosis, and hyperemia in the right eye. The condition worsened despite initial treatment with topical steroids. An orbital CT scan showed right eye proptosis, eyelid edema, and intraorbital fat stranding. A diagnosis of orbital inflammatory disease was made, and the patient was treated with high-dose oral steroids (prednisone 80 mg/day) tapered along 6 weeks...
June 2010: Osteoporosis International
(no author information available yet)
Zoledronic acid (Aclasta - Novartis) is the first bisphosphonate to be licensed in the UK as a once-yearly intravenous treatment for women with postmenopausal osteoporosis. Promotional materials claim that the drug "provides powerful osteoprotection with yearlong compliance", with "significant 3 year fracture reduction at all key sites". Here we consider whether zoledronic acid has a role in the treatment of women with postmenopausal osteoporosis.
December 2008: Drug and Therapeutics Bulletin
Emma D Deeks, Caroline M Perry
Zoledronic acid (Aclasta; Reclast), a third-generation nitrogen-containing bisphosphonate, is the first once-yearly treatment to have been approved for use in patients with postmenopausal osteoporosis or at high risk of fracture. Intravenous zoledronic acid 5 mg once yearly is effective in reducing the risk of several types of fracture in patients with postmenopausal osteoporosis or recent low-trauma hip fracture. Moreover, improvements in bone mineral density (BMD) and reductions in markers of bone turnover are also generally observed...
2008: Drugs & Aging
Gillian M Keating, Lesley J Scott
The third-generation, nitrogen-containing bisphosphonate zoledronic acid (Aclasta) is approved in the EU for the treatment of Paget's disease of bone. Results of well designed trials show that a single intravenous dose of zoledronic acid 5 mg is effective and well tolerated in the treatment of Paget's disease of bone. A single intravenous dose of zoledronic acid was associated with a significantly higher therapeutic response rate and a more rapid reduction in bone turnover than that achieved with 60 days of oral risedronic acid...
2007: Drugs
J J Body, J Sternon
Bone pain and bone deformities are the most common manifestations of Paget's disease of bone, even if the diagnosis is nowadays most often made by chance following a routine measurement of serum alkaline phosphatase. Woven bone is formed following a marked increase in bone resorption due to a stimulation of osteoclast activity. Biphosphonates constitute the modern treatment of Paget's disease of bone. Tiludronate (Skelid), or better risedronate (Actonel), are administered orally every day during at least 2 months...
November 2005: Revue Médicale de Bruxelles
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"